Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320254 | 0.75 | CYP3A4 (0.32) | CYP3A4TSHRMAPK1 | |
| SCHEMBL4249583 | 0.74 | — | — | |
| SCHEMBL28040406 | 0.73 | CYP3A4 (0.30) | CYP3A4TSHRMAPK1 | |
| SCHEMBL10319143 | 0.71 | PGK1 (0.30) | — | |
| SCHEMBL366710 | 0.71 | RAPGEF4 (0.39) | TSHR | |
| SCHEMBL27140744 | 0.67 | CA12 (0.33) | — | |
| SCHEMBL120101 | 0.66 | TSHR (0.39) | CYP3A4TSHRMAPK1 | |
| SCHEMBL1793576 | 0.65 | CYP1A2 (0.52) | CYP3A4TSHRMAPK1 | |
| SCHEMBL30010076 | 0.65 | CYP3A4 (0.33) | CYP3A4TSHRMAPK1 | |
| SCHEMBL5351238 | 0.65 | PGK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | disclosed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0873328-A1 | SUBSTITUTED 1,2,4,6-THIATRIAZINES USEFUL AS HERBICIDES | Novartis AG (CH) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997025319-A1 | SUBSTITUTED 1,2,4,6-THIATRIAZINES USEFUL AS HERBICIDES | NOVARTIS AG (CH) | 1997-07-17 | — | — | WO | disclosed |
| WO-1992010177-A1 | PHARMACEUTICAL COMPOSITIONS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | NR3C2, MGLL, GCG | CYP3A4 91/4885TSHR 1000/4885MAPK1 484/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | CYP3A4 91/4885TSHR 1000/4885MAPK1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.